Clinicopathologic features and diagnostic challenges of small cluster pattern appendiceal neuroendocrine tumors.

[1]  Aleeha Noon,et al.  Appendicitis Secondary to Obstructing Ascending Colon Malignancy , 2022, Cureus.

[2]  J. Cates,et al.  Risk factors for progression of appendiceal neuroendocrine tumours: low‐stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation , 2021, Histopathology.

[3]  A. Vanoli,et al.  Neuroendocrine neoplasms of the appendix, colon and rectum , 2021, Pathologica.

[4]  S. Mukhopadhyay,et al.  Combined Use of INSM1 and Synaptophysin Is the Most Sensitive and Specific Panel to Detect Neuroendocrine Neoplasms in the Digestive Tract. , 2020, American Journal of Clinical Pathology.

[5]  Monjur Ahmed.  Gastrointestinal neuroendocrine tumors in 2020 , 2020, World journal of gastrointestinal oncology.

[6]  Seung‐Mo Hong,et al.  Chromogranin A Expression in Rectal Neuroendocrine Tumors Is Associated With More Aggressive Clinical Behavior and a Poorer Prognosis , 2020, The American journal of surgical pathology.

[7]  S. Mukhopadhyay,et al.  INSM1 Is a Highly Specific Marker of Neuroendocrine Differentiation in Primary Neoplasms of the Gastrointestinal Tract, Appendix, and Pancreas. , 2020, American journal of clinical pathology.

[8]  G. Rossi,et al.  Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. , 2020, Annals of surgery.

[9]  A. Tabarin,et al.  Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study from the French Group of Endocrine Tumors (GTE). , 2019, Annals of surgery.

[10]  S. Mukhopadhyay,et al.  Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections , 2018, Modern Pathology.

[11]  M. Dietel,et al.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal , 2018, Modern Pathology.

[12]  K. Ding,et al.  Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population‐based study , 2018, Cancer medicine.

[13]  E. Felekouras,et al.  Neuroendocrine Neoplasms of the Appendix: A Review of the Literature. , 2018, Anticancer research.

[14]  N. Hiraoka,et al.  INSM1 expression and its diagnostic significance in extraskeletal myxoid chondrosarcoma , 2018, Modern Pathology.

[15]  Shouhao Zhou,et al.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States , 2017, JAMA oncology.

[16]  P. Illei,et al.  INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity , 2017, The American journal of surgical pathology.

[17]  A. Darzi,et al.  Surgical Management of Patients with Neuroendocrine Neoplasms of the Appendix: Appendectomy or More , 2017, Neuroendocrinology.

[18]  T. Fahey,et al.  Features Associated With Metastases Among Well-Differentiated Neuroendocrine (Carcinoid) Tumors of the Appendix: The Significance of Small Vessel Invasion in Addition to Size , 2015, Diseases of the colon and rectum.

[19]  D. Tyler,et al.  Management of 1- to 2-cm Carcinoid Tumors of the Appendix: Using the National Cancer Data Base to Address Controversies in General Surgery. , 2015, Journal of the American College of Surgeons.

[20]  M. Papotti,et al.  Tumor Staging But Not Grading Is Associated With Adverse Clinical Outcome in Neuroendocrine Tumors of the Appendix: A Retrospective Clinical Pathologic Analysis of 138 Cases , 2013, The American journal of surgical pathology.

[21]  E. Solcia,et al.  Pathology of gastrointestinal disorders. , 2010, Endocrinology and metabolism clinics of North America.

[22]  P. Möller,et al.  Expression of the natural killer cell-associated antigens CD56 and CD57 in human neural and striated muscle cells and in their tumors. , 1991, Cancer research.

[23]  D. Miller,et al.  Synaptophysin: a sensitive and specific marker for ganglion cells in central nervous system neoplasms. , 1990, Human pathology.

[24]  D. Nagorney,et al.  Carcinoid tumor of the appendix: treatment and prognosis. , 1987, The New England journal of medicine.